Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Managing pain can be a significant challenge, especially given the rising costs of healthcare. For many, the expense o ...

Mothers who lost their children to fentanyl deaths, from left, Laura Didier, Laura Collanton, Elizabeth Dillender and Gina ...

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada<p ...

Brian Shock, who had been in charge of the Cedar Falls Police Department’s crime lab, took Dr. Matthew Kettman to court for ...

When your dog has a cough, it can be unpleasant. Here are some vet recommended treatment options for cough suppressants for ...

Are you preparing for UPSC CSE Prelims 2025? Check your progress and revise your topics through this quiz on Science and ...

The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the urgent need ...

Bankrupt drugmaker Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

Vertex Pharmaceuticals is ranked among the best biotech stocks to buy, with 13 billionaires backing the company. Despite ...